Enanta Pharm (ENTA) Narrows Q2 Loss

Enanta Pharm (NASDAQ: ENTA) reported Q2 EPS of ($0.28), versus ($2.28) reported last year. Revenue for the quarter came in at $2.2 million, versus $1.2 million reported last year.

For earnings history and earnings-related data on Enanta Pharm (ENTA) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
• 15-Year-Old Egypt Dean Turns Kendrick Lamar Royalty Money Into Seven-Figure Investment in Ballislife Hydro Sports Drink